Oncology nursing

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Retrieved on: 
Tuesday, May 23, 2023

NUTLEY, N.J., May 23, 2023 /PRNewswire/ -- Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6.

Key Points: 
  • Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
  • A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • These abstracts will be made available on Thursday, May 25, 2023 at 5:00 PM EDT.

CURE Media Group announces Abbey Kaler, MS, APRN, FNP-C, CMSRN, as winner of 2023 Extraordinary Healer® Award

Retrieved on: 
Thursday, April 27, 2023

SAN ANTONIO, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- CURE®, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, has named Abbey Kaler, MS, APRN, FNP-C, CMSRN, the winner of the 2023 Extraordinary Healer award. At an awards ceremony at the San Antonio Marriott Rivercenter on the River Walk, Kaler was recognized for her tremendous dedication, expertise and helpfulness in caring for patients. Shannon Miller, seven-time Olympic medalist and cancer survivor, served as the event’s keynote speaker.

Key Points: 
  • Photo credit: Tammy Blalock
    “We are honored to celebrate the exceptional oncology nurses who demonstrate unwavering commitment to their patients,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, the parent company of CURE Media Group.
  • Kaler earned a Bachelor of Science degree in nursing at Baptist Health Sciences University in Memphis, Tennessee.
  • Founded in 2007, the annual Extraordinary Healer award has received hundreds of nominations and it continues to grow each year.
  • The men and women honored by the award have been nominated by colleagues, patients, friends, and family of outstanding oncology nurses throughout the country.

OncoHealth to Present How Technology Can Advance Oncology Patient Care at the 2023 ONS Congress

Retrieved on: 
Monday, April 24, 2023

ATLANTA, April 24, 2023 /PRNewswire/ -- OncoHealth®, a leading digital health company dedicated to oncology, will present at the 48th Annual ONS Congress on how a digital care management platform can provide positive value and impact by supporting patients who may otherwise not have access to holistic oncology care.

Key Points: 
  • ATLANTA, April 24, 2023 /PRNewswire/ -- OncoHealth®, a leading digital health company dedicated to oncology, will present at the 48th Annual ONS Congress on how a digital care management platform can provide positive value and impact by supporting patients who may otherwise not have access to holistic oncology care.
  • Iris by OncoHealth supports patients with cancer who may otherwise not have access to holistic oncology care.
  • "Iris is bringing tailored oncology care to patients when and where they need it through a first-of-its-kind digital platform available via smartphone," said Anju Chowattukunnel, BSN, RN, OCN, Senior Director of Oncology Nursing, OncoHealth.
  • "I'm proud our oncology nursing team is available 24/7 to provide immediate side effect and symptom management support.

2023 Oncology Nurse Advisor Summit Smashes Attendance Records

Retrieved on: 
Thursday, March 30, 2023

Over 1,415 oncology nurses in all roles found inspiration and connection while expanding their knowledge in disease-specific and supportive care topics on March 17-19 at the 2023 Oncology Nurse Advisor (ONA) Summit.

Key Points: 
  • Over 1,415 oncology nurses in all roles found inspiration and connection while expanding their knowledge in disease-specific and supportive care topics on March 17-19 at the 2023 Oncology Nurse Advisor (ONA) Summit.
  • The live virtual continuing education conference was hosted by Oncology Nurse Advisor—the Haymarket Medical Network (HMN) online and print resource for the oncology nurse community—in partnership with Haymarket Medical Education, Fox Chase Cancer Center and Temple University.
  • In addition to the partnership with Fox Chase Cancer Center, 2023 ONA Summit Sponsors included Regeneron (Platinum Sponsor) and AstraZeneca Pharmaceuticals (Silver Sponsor).
  • Creation of the virtual environment and production of the 2023 ONA Summit was provided by Haymarket’s sister organization, National Association for Continuing Education (NACE) Studios located in Sunrise, Florida.

CURE Media Group Announces the 2023 Extraordinary Healer® Award Finalists

Retrieved on: 
Tuesday, March 28, 2023

SAN ANTONIO, Texas, March 28, 2023 (GLOBE NEWSWIRE) -- CURE®, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, today announced the finalists for the 2023 Extraordinary Healer® award.

Key Points: 
  • SAN ANTONIO, Texas, March 28, 2023 (GLOBE NEWSWIRE) -- CURE®, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, today announced the finalists for the 2023 Extraordinary Healer® award.
  • “These individuals are truly remarkable, and we express our gratitude for their unwavering devotion to their patients and for positively impacting the lives of numerous people.”
    The finalists for the 2023 Extraordinary Healer® award are:
    Mary Colasuonno, B.S.N., RN, BMTCN.
  • CURE’s Extraordinary Healer® award celebration will feature a keynote address by Shannon Miller, seven-time Olympic medalist, mother of two and cancer survivor.
  • For more information on the 2023 Extraordinary Healer® event, click here.

Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer

Retrieved on: 
Sunday, March 26, 2023

LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.

Key Points: 
  • LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.
  • "We are pleased to present additional data with nab-sirolimus from our AMPECT trial and highlight our PRECISION 1 trial at SGO 2023, which is the premier medical meeting focused on advancing research for gynecologic cancer," said Loretta Itri, MD., Chief Medical Officer of Aadi Bioscience.
  • The details of the poster presentations are below:
    Title: "Response to treatment with nab-sirolimus among patients with primary uterine PEComa: A sub analysis from AMPECT"
    The Society of Gynecological Oncology Annual Meeting on Women's Cancer is the premier educational and scientific event for those who treat and care for women with gynecologic cancer.
  • Abstracts and full session details are available through the SGO Annual Meeting planner: Annual Meeting on Women's Cancer | SGO .

U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

Retrieved on: 
Friday, March 3, 2023

INDIANAPOLIS, March 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following: tumors that are ≥5 cm or Grade 3).1 This expanded adjuvant indication removes the Ki-67 score requirement for patient selection.

Key Points: 
  • The addition of Verzenio to ET reduced the risk of recurrence by 35% compared to ET alone (HR=0.653 [95% CI: 0.567-0.753]).
  • "Our goal in intensifying treatment for early breast cancer is to maintain remission and prevent the recurrence of cancer.
  • "A significant number of women and men have HR+, HER2- early breast cancer at high risk of returning.
  • We're pleased Verzenio will now be available to more people with this type of early breast cancer."

Theratechnologies Announces Path to Resume TH1902 Clinical Development

Retrieved on: 
Thursday, February 16, 2023

Following a voluntary pause in the study’s enrollment on December 1, 2022, the Company formed a Scientific Advisory Committee (SAC) to help determine the best developmental path forward for TH1902.

Key Points: 
  • Following a voluntary pause in the study’s enrollment on December 1, 2022, the Company formed a Scientific Advisory Committee (SAC) to help determine the best developmental path forward for TH1902.
  • The Company will continue to seek advice and input from Mace Rothenberg, MD, who is currently a scientific advisor to Theratechnologies.
  • “We are eager to resume patient enrollment with a revised protocol for TH1902 and have pulled together some of the best scientists in the field of oncology drug development to ensure an optimal amendment,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies.
  • Once the Phase 1 clinical trial has resumed, Theratechnologies will also evaluate potential partnerships for TH1902.

BioSkryb Announces Commercial Launch of ResolveOME System and BaseJumper Bioinformatics Platform

Retrieved on: 
Tuesday, February 7, 2023

BioSkryb Genomics , a pioneer in comprehensive single cell multiomic research solutions, today announced the commercial launch of its ResolveOME™ Whole Genome and Transcriptome Amplification system and BaseJumper™ Bioinformatics Platform at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting.

Key Points: 
  • BioSkryb Genomics , a pioneer in comprehensive single cell multiomic research solutions, today announced the commercial launch of its ResolveOME™ Whole Genome and Transcriptome Amplification system and BaseJumper™ Bioinformatics Platform at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting.
  • When coupled with BioSkryb’s BaseJumper Bioinformatics platform, which provides simple and dynamic visualization of multiomic findings, investigators can now comprehensively explore the cellular ecosystem to enhance our understanding of complex human disease.
  • However, the ResolveOME system addresses these limitations through its breakthrough single cell whole-genome amplification (WGA) technique utilizing proprietary and patented Primary Template-directed Amplification (PTA), along with full-transcript reverse transcription.
  • “We are thrilled to make our ResolveOME system widely available after the successful completion of our Early Access Program with key scientific partners,” said Suresh Pisharody, CEO of BioSkryb.

Olympus Technologies Featured in Several Experience Papers on Energy Advancements

Retrieved on: 
Monday, January 23, 2023

CENTER VALLEY, Pa., Jan. 23, 2023 /PRNewswire/ -- Olympus announced today the availability of several Experience Papers focused on the benefits of advancements in electrosurgical devices. Important to the broad range of minimally invasive surgical solutions available to patients, electrosurgical or "energy" devices are designed to allow for efficient dissection and cauterization of tissue. Many times, as explained in these papers, they also contribute to improved workflow in the procedure room. Among these papers developed for a healthcare professional audience, benefits of workflow, ergonomics, cost reduction and control of energy-related smoke were discussed.

Key Points: 
  • Important to the broad range of minimally invasive surgical solutions available to patients, electrosurgical or "energy" devices are designed to allow for efficient dissection and cauterization of tissue.
  • Many times, as explained in these papers, they also contribute to improved workflow in the procedure room.
  • Among these papers developed for a healthcare professional audience, benefits of workflow, ergonomics, cost reduction and control of energy-related smoke were discussed.
  • More information about the Olympus Energy devices included in these Experience Papers can be found here: